Glenmark Pharmaceuticals Ltd in the third week of August 2014 unveiled a new anti-cancer drug called GBR 1302. It is the first clinical development candidate in the antibody based cancer therapy group.
The drug is a novel biological molecule similar to exiting antibody cancer drugs trastuzumab andpertuzumab, which will be used in the treatment of breast and ovarian cancers.
GBR 1302’s mode of action is different from the existing drugs in this class as it kills cancer cells more rapidly and completely. It is also not subject to the same resistance escape mechanisms as the existing therapies.
About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.
It manufactures and markets generic formulation products and active pharmaceutical ingredients (API), both in the domestic and international markets.
In the formulation business, its business spans segments such as Dermatology, Internal Medicine, Paediatrics, Gynaecology, ENT and Diabetes.
It has four manufacturing facilities for formulations and additional three facilities for APIs. These manufacturing facilities are located in the states of Maharashtra, Goa, Himachal Pradesh and Gujarat in India.
It operates in 95 countries through its subsidiaries, Glenmark Pharmaceuticals USA, Glenmark Pharmaceuticals UK and Glenmark Pharmaceuticals SA.
If you have any Question/Point on the above information, please ask/discuss it in the Current Affairs Group
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.